| Dr Kapil Kohli, MD | |
|
4401 Wornall Rd, Kansas City, MO 64111-3220 | |
| (816) 932-0340 | |
| (816) 932-3148 |
| Full Name | Dr Kapil Kohli |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 23 Years |
| Location | 4401 Wornall Rd, Kansas City, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912177882 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 2011011829 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Iberia Medical Center | New iberia, LA | Hospital |
| Christus Health Shreveport - Bossier | Shreveport, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Main Street Physician Services Llc | 8022331909 | 21 |
News Archive
Scientists at A*STAR's Institute of Medical Biology (IMB) and Institute of Molecular and Cellular Biology (IMCB) have identified a gene encoding a hormone that could potentially be used as a therapeutic molecule to treat heart diseases.
Australian researchers have discovered that more than one quarter of men with hemochromatosis develop liver cancer, arthritis and other complications.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
The emergence of new pathogens like West Nile Virus, Ebola, Dengue, and Zika, threaten human health on a global scale.
› Verified 7 days ago
| Entity Name | Wk Pierremont Hospitalists |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326074832 PECOS PAC ID: 4082669015 Enrollment ID: O20050314000130 |
News Archive
Scientists at A*STAR's Institute of Medical Biology (IMB) and Institute of Molecular and Cellular Biology (IMCB) have identified a gene encoding a hormone that could potentially be used as a therapeutic molecule to treat heart diseases.
Australian researchers have discovered that more than one quarter of men with hemochromatosis develop liver cancer, arthritis and other complications.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
The emergence of new pathogens like West Nile Virus, Ebola, Dengue, and Zika, threaten human health on a global scale.
› Verified 7 days ago
| Entity Name | Minden Physician Practices Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497986764 PECOS PAC ID: 4789720004 Enrollment ID: O20090930000103 |
News Archive
Scientists at A*STAR's Institute of Medical Biology (IMB) and Institute of Molecular and Cellular Biology (IMCB) have identified a gene encoding a hormone that could potentially be used as a therapeutic molecule to treat heart diseases.
Australian researchers have discovered that more than one quarter of men with hemochromatosis develop liver cancer, arthritis and other complications.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
The emergence of new pathogens like West Nile Virus, Ebola, Dengue, and Zika, threaten human health on a global scale.
› Verified 7 days ago
| Entity Name | Main Street Physician Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396150785 PECOS PAC ID: 8022331909 Enrollment ID: O20141229001749 |
News Archive
Scientists at A*STAR's Institute of Medical Biology (IMB) and Institute of Molecular and Cellular Biology (IMCB) have identified a gene encoding a hormone that could potentially be used as a therapeutic molecule to treat heart diseases.
Australian researchers have discovered that more than one quarter of men with hemochromatosis develop liver cancer, arthritis and other complications.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
The emergence of new pathogens like West Nile Virus, Ebola, Dengue, and Zika, threaten human health on a global scale.
› Verified 7 days ago
| Entity Name | Hospitalist Medicine Physicians Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629307095 PECOS PAC ID: 3476688318 Enrollment ID: O20151021000365 |
News Archive
Scientists at A*STAR's Institute of Medical Biology (IMB) and Institute of Molecular and Cellular Biology (IMCB) have identified a gene encoding a hormone that could potentially be used as a therapeutic molecule to treat heart diseases.
Australian researchers have discovered that more than one quarter of men with hemochromatosis develop liver cancer, arthritis and other complications.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
The emergence of new pathogens like West Nile Virus, Ebola, Dengue, and Zika, threaten human health on a global scale.
› Verified 7 days ago
| Entity Name | Lsu Health Sciences Center Shreveport Faculty Group Practice |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013374222 PECOS PAC ID: 4082902721 Enrollment ID: O20161012000307 |
News Archive
Scientists at A*STAR's Institute of Medical Biology (IMB) and Institute of Molecular and Cellular Biology (IMCB) have identified a gene encoding a hormone that could potentially be used as a therapeutic molecule to treat heart diseases.
Australian researchers have discovered that more than one quarter of men with hemochromatosis develop liver cancer, arthritis and other complications.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
The emergence of new pathogens like West Nile Virus, Ebola, Dengue, and Zika, threaten human health on a global scale.
› Verified 7 days ago
| Entity Name | Hni Medical Services At Glenwood Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669962064 PECOS PAC ID: 0547518920 Enrollment ID: O20180801000659 |
News Archive
Scientists at A*STAR's Institute of Medical Biology (IMB) and Institute of Molecular and Cellular Biology (IMCB) have identified a gene encoding a hormone that could potentially be used as a therapeutic molecule to treat heart diseases.
Australian researchers have discovered that more than one quarter of men with hemochromatosis develop liver cancer, arthritis and other complications.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
The emergence of new pathogens like West Nile Virus, Ebola, Dengue, and Zika, threaten human health on a global scale.
› Verified 7 days ago
| Entity Name | Cogent Healthcare Of Texas Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992722953 PECOS PAC ID: 8628076924 Enrollment ID: O20190923002250 |
News Archive
Scientists at A*STAR's Institute of Medical Biology (IMB) and Institute of Molecular and Cellular Biology (IMCB) have identified a gene encoding a hormone that could potentially be used as a therapeutic molecule to treat heart diseases.
Australian researchers have discovered that more than one quarter of men with hemochromatosis develop liver cancer, arthritis and other complications.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
The emergence of new pathogens like West Nile Virus, Ebola, Dengue, and Zika, threaten human health on a global scale.
› Verified 7 days ago
| Entity Name | Sound Inpatient Physicians Of Texas I, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811321797 PECOS PAC ID: 8729133640 Enrollment ID: O20200123001338 |
News Archive
Scientists at A*STAR's Institute of Medical Biology (IMB) and Institute of Molecular and Cellular Biology (IMCB) have identified a gene encoding a hormone that could potentially be used as a therapeutic molecule to treat heart diseases.
Australian researchers have discovered that more than one quarter of men with hemochromatosis develop liver cancer, arthritis and other complications.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
The emergence of new pathogens like West Nile Virus, Ebola, Dengue, and Zika, threaten human health on a global scale.
› Verified 7 days ago
| Entity Name | Lc Hospital Medicine Physicians, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417654724 PECOS PAC ID: 9739546805 Enrollment ID: O20230605001940 |
News Archive
Scientists at A*STAR's Institute of Medical Biology (IMB) and Institute of Molecular and Cellular Biology (IMCB) have identified a gene encoding a hormone that could potentially be used as a therapeutic molecule to treat heart diseases.
Australian researchers have discovered that more than one quarter of men with hemochromatosis develop liver cancer, arthritis and other complications.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
The emergence of new pathogens like West Nile Virus, Ebola, Dengue, and Zika, threaten human health on a global scale.
› Verified 7 days ago
| Entity Name | Northeast Louisiana Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407637671 PECOS PAC ID: 2365885944 Enrollment ID: O20240212000148 |
News Archive
Scientists at A*STAR's Institute of Medical Biology (IMB) and Institute of Molecular and Cellular Biology (IMCB) have identified a gene encoding a hormone that could potentially be used as a therapeutic molecule to treat heart diseases.
Australian researchers have discovered that more than one quarter of men with hemochromatosis develop liver cancer, arthritis and other complications.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
The emergence of new pathogens like West Nile Virus, Ebola, Dengue, and Zika, threaten human health on a global scale.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kapil Kohli, MD 901 E 104th St, Kansas City, MO 64131-4517 Ph: (816) 502-8752 | Dr Kapil Kohli, MD 4401 Wornall Rd, Kansas City, MO 64111-3220 Ph: (816) 932-0340 |
News Archive
Scientists at A*STAR's Institute of Medical Biology (IMB) and Institute of Molecular and Cellular Biology (IMCB) have identified a gene encoding a hormone that could potentially be used as a therapeutic molecule to treat heart diseases.
Australian researchers have discovered that more than one quarter of men with hemochromatosis develop liver cancer, arthritis and other complications.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
The emergence of new pathogens like West Nile Virus, Ebola, Dengue, and Zika, threaten human health on a global scale.
› Verified 7 days ago
Subashis Paul, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 2301 Main St, Kansas City, MO 64108 Phone: 816-395-3558 | |
Tyler Porter, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 | |
Christine M. Sankpill, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
Anuhya Caipa Young, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
David A Wooldridge, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
Peter Lebourveau, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
David C Hermanns, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2301 Holmes St, Kansas City, MO 64108 Phone: 816-404-1000 |